Here are the 424B prospectus supplements from Vivos Therapeutics, Inc. (VVOS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VVOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VVOS filings page.
Vivos Therapeutics, Inc. registers 3,964,712 shares of Common Stock for resale, consisting of 1,982,356 shares issuable upon exercise of a five-year Series A Warrant and 1,982,356 shares issuable upon exercise of a 24‑month Series B Warrant. The resale is by a selling stockholder; the company will not receive proceeds from sales but may receive proceeds if the Warrants are exercised for cash.
The prospectus states the Warrants were issued in a January 20, 2026 warrant inducement private placement and that the selling stockholder may sell shares at prevailing market prices, through brokers or negotiated transactions, at its sole discretion. The filing discloses the Company will bear registration expenses and that as of May 7, 2026 the last reported sale price was $0.66 per share; there were 13,714,329 shares outstanding as of that date.
Vivos Therapeutics is registering 1,982,356 shares of common stock for resale by a single institutional holder, Armistice Capital, issuable upon exercise of three previously issued warrants from January 2023, November 2023 and February 2024. Vivos will not sell any shares in this offering and will not receive proceeds from resale, but could receive up to approximately $8,489,485 if the warrants are exercised for cash. As of January 12, 2026, 9,437,788 shares of common stock were outstanding. The company discloses significant additional outstanding warrants, notes that large future sales could pressure its share price and highlight risks of dilution, financing needs and stock price volatility as it pursues a new sleep-center–focused growth model.